Latest Content

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a Phase 3 clinical trial.

Daily practices help one writer find calm and stability while living with multiple myeloma.

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions.

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.

Lauren Yerkes shares how her breast cancer diagnosis uncovered generations of genetic information for her family.

Olympians’ resilience and joy offer lessons in strength and support for patients with cancer.

The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 neutropenia and septic shock.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

In a trial of 171 women, app-based self-acupressure improved fatigue vs usual care, offering a low-cost option for ovarian cancer survivors.

My daughter is happy to tell her story so that others can learn that there is hope in the face of despair.

The U.S. FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer.

Five-year follow-up of cryoablation for small kidney tumors shows high recurrence-free rates and a minimally invasive option for select patients.

FDA granted fast track designation to AKY-1189 for adults with metastatic urothelial cancer after systemic therapy, aiming to speed development of the investigational drug.